Scientists agree that the next flu pandemic is a matter of when, not if.
EnGen Bio is developing a therapy and vaccine to provide lifetime immunity to Type A flu.

EnGen’s independent research lab is testing development of a universal vaccine for Type A influenza, which causes swine flu, avian flu, and seasonal flu.

We've discovered influenza's "Achilles' heel"

Unlike conventional flu vaccines, which are generally hemagglutinin or whole-virus based, our vaccine targets a region, a novel epitope on the flu virus’s M1 matrix protein, to elicit potentially long-lasting and broadly neutralizing antibody responses in both humans and animals.
Learn more about our science 

A global initiative for a global problem

The size, scope and urgency of this endeavor is why the National Institutes of Health, Department of Defense, Department of Agriculture, and the Bill and Melinda Gates Foundation are focused on funding companies that are developing drug and vaccine candidates that target influenza.

We've achieved an important preclinical milestone.

Invest in preventing the next pandemic

We already have nine patents protecting our valuable discoveries. Help us accelerate our early stage vaccine development program to address the $8B potential of this market, including $6B human, $0.5B veterinary and $2B flu treatment antibody sectors.